ArticleEJNMMI radiopharmacy and chemistry2025

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Myrna Luna-Gutiérrez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.